Esperion (NASDAQ: ESPR) today announced the establishment of its
Scientific Advisory Board (SAB). The inaugural members of the
Esperion SAB represent a diverse group of internationally renowned
experts who will bring a depth and breadth of basic, translational,
and clinical research experience across several key therapeutic
areas that will inform our research and development strategy moving
forward. The members of the SAB are at the forefront of research in
atherosclerosis and atherosclerotic cardiovascular disease,
inflammation, metabolic disorders, and non-alcoholic
steatohepatitis/non-alcoholic fatty liver disease.
“This is a crucial time for Esperion with our CLEAR
Outcomes trial reading out in the coming months and major pipeline
developments underway,” said Sheldon Koenig, president and chief
executive officer of Esperion. “The insights and recommendations of
our SAB members will play a key role in guiding the future of
Esperion and optimizing the potential of both our currently
marketed products, and the investigational assets in our pipeline,
including an oral PCSK9 inhibitor and ATP citrate lyase inhibitors.
You will hear more about these programs at our R&D Day on
November 9.”
The Esperion SAB will be co-chaired by the renowned
physician-scientist Peter Libby, MD, FAHA, Cardiovascular
Specialist at Brigham and Women’s Hospital, current president of
the International Atherosclerosis Society, and member of the
executive committee for Esperion’s CLEAR Outcomes (Cholesterol
Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) study, and
Joanne Foody, MD, FACC, FAHA, Chief Medical Officer of
Esperion.
The inaugural members of Esperion’s SAB
are:
Peter Libby, MD, FAHA is a
cardiovascular specialist at Brigham and Women’s Hospital in
Boston, Massachusetts. His areas of clinical expertise include
general and preventive cardiology. His current major research focus
is the role of inflammation in vascular diseases such as
atherosclerosis. Dr. Libby has a particular devotion to translating
his basic laboratory studies to pilot and then large-scale clinical
cardiovascular outcome trials. He instigated and helped to lead the
large scale Canakinumab Anti-Inflammatory Thrombosis Outcomes Trial
(CANTOS) that provided clinical validation of the role of
inflammation in atherosclerosis.
Jeffrey Bender, MD is a
cardiologist, researcher and immunobiologist who cares for patients
with cardiovascular (CV) issues and disorders, ranging from CV
prevention to angina, heart failure, and atrial fibrillation. Dr.
Bender is the Robert I. Levy Professor of Preventive Cardiology and
a Professor of Immunobiology at the Yale School of Medicine, as
well as the Senior Vice Chief for academic development in the
Cardiovascular Medicine division. He also established
the Yale-Cambridge Program in Cardiovascular Research that focuses
on arteriosclerosis, angiogenesis, vascular injury, and
transplantation.
Erin A. Bohula, MD, DPhil is a
cardiovascular medicine and critical care specialist at Brigham and
Women’s Hospital. In addition, she is an Assistant Professor at
Harvard Medical School, a staff investigator for the Thrombolysis
in Myocardial Infarction (TIMI) Study Group, and a founding member
of the Critical Care Cardiology Trials Network. Her research
interests include pharmacologic interventions for cardiometabolic
disease, such and hyperlipidemia and obesity, as well as expanding
the evidence base for management of critically ill cardiovascular
patients.
Karin Bornfeldt, PhD, FAHA is the
Edwin L. Bierman Professor of Medicine and Professor of Laboratory
Medicine and Pathology. She also serves as Director of the Diabetes
Complications Program of the UW Medicine Diabetes Institute, and
Deputy Director of the Diabetes Research Center at the University
of Washington. She is a Consulting Editor for Arteriosclerosis,
Thrombosis and Vascular Biology, and an Associate Editor for
Circulation Research, and the Journal of Lipid Research. Her
research focuses on cardiovascular complications of diabetes, with
a particular emphasis on the role of lipoproteins.
Dennis Bruemmer, MD, PhD is a
cardiologist and the Director of the Center for
Cardiometabolic Health in the Section of Preventive Cardiology
and Rehabilitation in the Robert and Suzanne Tomsich Department of
Cardiovascular Medicine of the Sydell and Arnold Miller Family
Heart, Vascular & Thoracic Institute. He is a Professor of
Medicine at Cleveland Clinic Lerner School of Medicine Case Western
Reserve Medical School. He specializes in preventive
cardiology, particularly in the comprehensive management of
cardiovascular risk and metabolic control of patients with
diabetes.
David E. Cohen, MD, PhD is a
hepatologist and the Chief of the Division of Gastroenterology,
Hepatology & Endoscopy at Brigham and Women’s Hospital and
Professor of Medicine at Harvard Medical School. For more than 25
years his laboratory research programs have focused on
understanding the molecular regulation of hepatic lipid and glucose
metabolism. His studies are also examining nonalcoholic fatty liver
disease (NAFLD) while unraveling the key aspects of this condition
and its risk factors, which are implicated in obesity-related
disorders (e.g., NAFLD, type 2 diabetes, coronary artery disease,
as well as an increased predisposition to cancer).
Gabrielle Fredman, PhD is an
Associate Professor of Molecular and Cellular Pathology at Albany
Medical College. She is the principal investigator of an NIH-funded
research laboratory focused on identifying cellular and molecular
mechanisms underlying failed inflammation-resolution programs in
atherosclerosis and aging. Dr. Fredman is also passionate about
research of inflammation, resolution of inflammation, lipid
mediators, and macrophages. Marilyn Glassberg, MD
is a pulmonologist with expertise in interstitial and rare lung
diseases, John W. Clarke Endowed Professor, and Chair of the
Department of Medicine for the Loyola University of Chicago Stritch
School of Medicine. She was the inaugural division Chief of
pulmonary medicine, critical care, and sleep medicine; the
Vice-Chair for diversity and inclusion, as well as senior director
of clinical research and strategy and growth for the Department of
Internal Medicine for the University of Arizona College of
Medicine-Phoenix and Banner University Medical Center for the past
3 years. Dr. Glassberg has spearheaded “bench to bedside” medicine
by conducting National Institutes of Health, industry-sponsored and
investigator-initiated clinical trials in patients with idiopathic
pulmonary fibrosis.
R. Preston Mason, MBA, PhD is on
the faculty of the Department of Medicine, Division of Cardiology,
at Brigham and Women's Hospital in Boston, Massachusetts. He is
also President and Founder of Elucida Research, a private
biotechnology firm, in Beverly, Massachusetts. Research interests
include membrane biophysics, mechanisms of cholesterol
crystallization in plaque and the response of the endothelium to
oxidative stress and inflammation. Dr. Mason serves on a number of
grant review committees, has authored more than 175 full scientific
publications, and has multiple patents.
Pradeep Natarajan, MD, MMSc is a
cardiologist and the Director of Preventive Cardiology and the Paul
and Phyllis Fireman Endowed Chair in Vascular Medicine at
Massachusetts General Hospital (MGH), Associate Professor of
Medicine at Harvard Medical School, Associate Member of the Broad
Institute of Harvard and MIT. He also oversees the clinical
and training programs on the prevention of cardiometabolic diseases
leading the MGH Cardiovascular Disease Prevention Center Dr.
Natarajan uses germline and somatic genetic variation to uncover
new biology and enable enhanced clinical care for cardiovascular
disease.
Gerald I. Shulman, MD, PhD, MACP, MACE,
FRCP is an endocrinologist and a George R. Cowgill
Professor of Medicine (Endocrinology) and Professor of Cellular and
Molecular Physiology at Yale. He is also Co-Director of the Yale
Diabetes Research Center. Dr. Shulman has pioneered the use of
magnetic resonance spectroscopy combined with mass spectrometry to
non-invasively examine intracellular glucose and fat metabolism in
humans and transgenic rodent models that have led to several
paradigm shifts in our understanding of type 2
diabetes.
Esperion
Therapeutics Esperion works hard to make our
medicines easy to get, easy to take and easy to have. We discover,
develop and commercialize innovative medicines and combinations to
lower cholesterol, especially for patients whose needs aren’t being
met by the status quo. Our entrepreneurial team of industry leaders
is inclusive, passionate and resourceful. We are singularly focused
on managing cholesterol so you can improve your health easily. For
more information, please visit www.esperion.com and follow us on
Twitter at www.twitter.com/EsperionInc.
Forward-Looking
Statements This press release contains
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including
statements regarding future operations, commercial products,
clinical development including the timing, designs and plans for
the CLEAR Outcomes study and its results, plans for potential
future product candidates, and other statements containing the
words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the impact of the ongoing
COVID-19 pandemic on our business, revenues, results of operations
and financial condition, the net sales, profitability, and growth
of Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, and the
risks detailed in Esperion’s filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact: Corporate
Communications corporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024